Scienture Holdings Inc (SCNX)

Much appreciated: Thanks for saying.

There is a market for both dosages. When life is at risk, EMTs will want to administer the stronger dose to get the job done. If they wait to see the effects of the lighter dose and the patient dies, they expose themselves to liability claims. However, if they give the large dose, their defense is they gave the strongest dosage available. Any side effects are lesser than death.
After it's in use for a while, it will likely be available OTC and could displace Narcan entirely.
As far as that goes, I'd also want to give the big dose for the same reasons. Plus, if someone has side effects, too bad -- don't do the drug(s) if you don't want the consequences of attempting to save them.
Good luck, longs.

In case you don't know: https://www.google.com/search?q=narcan+compared+to+REZENOPY&sourceid=chrome&ie=UTF-8&amc=1&udm=50&aep=42&cud=0&source=chrome.crn.rb&mstk=AUtExfCYcv0rIuPZ6TkUmiVsD4l9_Jp71v-Uvo1GS4tFrWVOaBP9-GANTx6mGy8pePnNig4YEI7xViCWpG9nNEmLjAQR6oVLBzRLl30bq3tSc0dY5JSZddw3vIhlifCcANb5EEO_KkqBab9XnRY9t_hBKHW8fUb3LQoeZts&csuir=1https://www.google.com/search?q=narcan+compared+to+REZENOPY&sourceid=chrome&ie=UTF-8&amc=1&udm=50&aep=42&cud=0&source=chrome.crn.rb&mstk=AUtExfCYcv0rIuPZ6TkUmiVsD4l9_Jp71v-Uvo1GS4tFrWVOaBP9-GANTx6mGy8pePnNig4YEI7xViCWpG9nNEmLjAQR6oVLBzRLl30bq3tSc0dY5JSZddw3vIhlifCcANb5EEO_KkqBab9XnRY9t_hBKHW8fUb3LQoeZts&csuir=1

Smells good to me under $.40

Scienture secures GPO agreements for REZENOPY naloxone nasal sprayMarch 11, 2026 11:23 AM
IH Market News
Scienture Holdings Inc. (NASDAQ:SCNX) announced that it has signed several Group Purchasing Organization (GPO) agreements covering its REZENOPY (naloxone HCl) Nasal Spray 10 mg, according to a company press release.Through these agreements, the product will gain access to more than 5,000 healthcare institutions across the United States. These include hospitals, clinics, nursing homes, emergency medical services providers, first responders and rehabilitation centers. The company said the arrangements could enable REZENOPY to reach roughly 60% of the U.S. institutional healthcare market.REZENOPY is a 10 mg naloxone nasal spray approved by the U.S. Food and Drug Administration on April 19, 2024, for the emergency treatment of known or suspected opioid overdoses in both adult and pediatric patients. The product is packaged in cartons containing two single-use intranasal spray devices.According to market data from IQVIA cited by the company, the U.S. naloxone market generated approximately $141 million in annual sales as of January 2026, with about 9.4 million prescription units dispensed.The commercial expansion comes as Scienture faces ongoing financial challenges. The company’s shares currently trade around $0.39, close to a 52-week low of $0.37, and have declined roughly 69% over the past year. Despite reporting revenue growth of 208% over the last twelve months, the company remains unprofitable with a loss per share of $1.57 and maintains a market capitalization of about $15.8 million.“These GPO agreements represent a significant step forward in the commercial expansion of REZENOPY,” said Narasimhan Mani.Scienture noted that its gross profit margins currently stand at approximately 88%, and analysts expect sales growth during the current year.The company’s subsidiary Scienture LLC obtained exclusive U.S. commercialization rights for REZENOPY in March 2025 through an agreement with Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P..REZENOPY is contraindicated in patients with known hypersensitivity to naloxone hydrochloride. Safety warnings include risks such as recurrent respiratory depression, limited effectiveness with certain opioid types, severe opioid withdrawal symptoms and potential cardiovascular effects. Clinical studies have reported adverse reactions including upper abdominal pain, nasopharyngitis and dysgeusia.Scienture operates primarily through Scienture LLC and focuses on developing and commercializing specialty pharmaceutical products.In other recent developments, Scienture announced expanded access for its liquid losartan product ARBLI after securing multiple pharmacy benefit manager rebate agreements and institutional GPO contracts. The expansion provides access to more than 2,500 healthcare facilities and covers over 100 million patients through major national health plans.The company also confirmed plans to launch REZENOPY commercially in the second quarter of 2026, with distribution to wholesale channels expected to begin in the first quarter of the same year.Separately, the United States Patent and Trademark Office granted a patent covering the REZENOPY nasal spray formulation, providing intellectual property protection until February 2041. The patent was issued to Summit Biosciences, the Kindeva subsidiary that developed the product.REZENOPY, approved by the FDA in April 2024, is described as the highest-strength naloxone nasal spray currently available for emergency treatment of suspected opioid overdoses.Scienture Holdings stock price

Original: Scienture secures GPO agreements for REZENOPY naloxone nasal spray

SCNX news .. SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
https://finance.yahoo.com/news/scienture-broadens-commercial-access-rezenopy-120500266.html

When does ths stock become bullish? Always dump dump dump on good news.

SCNX.......................................https://stockcharts.com/sc3/ui/?s=SCNX&p=W&b=5&g=0&id=p86431144783

$SCLX $DVLT Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI
https://www.globenewswire.com/news-release/2025/11/04/3180059/0/en/Scilex-Holding-Company-Announces-Worldwide-Exclusive-License-for-Tokenization-and-Monetization-of-Real-World-Asset-RWA-in-Genomic-DNA-Data-Diagnosis-Therapeutics-Products-Genetic-a.html

To $2's again! $$$$$$$$$$$$$$$$$

SCNX, has the drug only approved by FDA . It's a huge markets.

Will bounce back to $2's ranges.

Yes. $$$$$$$$$$$$ To $1's again! $$$$$$$$$$$$$

SCNX, was $2.6 just 6 days ago:

2025-10-23, SCNX, $2.60, Volumes: 799,762,494

This is about to run again!

Very strong support at these levels. The tide is going to change . Tomorrow this will run very hard. Huge gap up in the premarket, Mark my post!

This is going

Fortunately I was able to sell at 2.80 after hours

Right now it’s at 1.90


Ec

You're not going to believe this but I sold at 12:59...at $2.60, put my sale order in at around 12:50 and then it was halted ( maybe 12:45), and right before the close they took it!!!

They halted the stock into the close of business

Is that fair??


Ec

scnx.....................................................https://stockcharts.com/sc3/ui/?s=SCNX&p=W&b=5&g=0&id=p86431144783/M

.81 exit take the cash $$ need money to market it

Hypertension liquid .78 

.61 pump it

Are you on the right board

$SCNX : Wow....... PM fire....... now $1.30

Monster mover......................... OpenAI deal or something ????


GO $SCNX

SCNX...............................................p/m

Cash out 1.35 need a big Pharma company help otherwise to expensive to compete in a bug Pharma guys  market  

$1.20 drink that high blood pressure medicine instead of pills ARBLI pump 

SCNX pump time back .97 cents 

$1.05 on news sell it at $1.18 wuick 10%

SCNX..................................................................https://stockcharts.com/h-sc/ui?s=SCNX&p=W&b=5&g=0&id=p86431144783

SCNX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://stockcharts.com/h-sc/ui?s=SCNX&p=W&b=5&g=0&id=p86431144783

SCNX...$1.92...🥳...Off the $1.76 Dip Alert...

georgie18

Member Level
Re: 81vette post# 677215

Tuesday, March 18, 2025 3:33:32 PM

Post#
677216
of 677252
SCNX...$1.76...🥳...Bouncing off the $1.50 Range dip ...47,000 share bidder at $1.75...

Sounds promising
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCNX...$1.76...🥳...Bouncing off the $1.50 Range dip ...47,000 share bidder at $1.75...

scnx.................................................................................p/m

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218772s000lbl.pdf

drug might be approved,just waiting on this label approval,don’t know why they would make info label without drug approval?
We should know soon,maybe in morning

Glad to help

Ahhhhh i kind of understand Thankyou Thankyou for the explanation! really appreciate it! not financial advice

Yw,I watch the shares to borrow,when they are dropping,ticker can move up,and when it hits zero borrow,the ticker moves freely and fast because it’s not being manipulated by shorts,and if it does move 20%+ at some point they have to cover and a ticker can really fly up with buying and covering(buying also)

Thankyou Thankyou for the response i appreciate it! So basically let them do their thing and when they exit thats when it can start to go super? Not financial advice

$SCNX: AH mover...... over $3 now

This is one to watch tomorrow........... maybe $6 breaker possible.

I wouldn't be surprised if such is the case.

Drumpf would support this


GO $SCNX

🚀💵Bang 

Zero borrow is when their are no shares to loan out to short,not fighting the shorts is key to winning a trade. Go to shortablestocks.com ,sign up for free ,I wouldn’t trade without it!!

Resistance,sma 50[@ 3.40 ,sma200 @ 7.35 mental 5 10 15 previous high 8 before dec drop to pay for debt of buying distribution co
Potential is huge with these drugs they have.and they bought a distribution co and have manufacturer deals also. 49% insiders own so they believe in themselves at least lol

Hi may i please ask if you dont mind what you mean by zero borrows? Does that mean the stock can go super? Thankyou! not financial advice

$SCNX: Looks like it panned out after all


Now $2.40.................. good call.

Whats the max level on this now ??

Some calling REZNOPY to get it to $10 ????


GO $SCNX

*************************************************************************



SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
March 06, 2025 07:40 ET
| Source: Scienture Holdings, Inc.

Share






TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.

Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY® (naloxone HCl) Nasal Spray 10mg. Scienture will own the new drug application (NDA) for REZENOPY® in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture’s commercial operations infrastructure.

REZENOPY® is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids.

The addition of REZENOPY® to Scienture’s product portfolio aligns with Scienture’s mission to provide innovative treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose. As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and advocacy groups to enhance awareness, education, and distribution efforts.

Nasal delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market.

“We are proud to take this significant step in strengthening our commitment to combating the opioid epidemic,” said Narasimhan Mani, Ph.D., MBA, President of Scienture, LLC. “Through this collaboration with a well established and strong partner like Kindeva, we now offer REZENOPY®, a higher dose naloxone HCl option for communities, reinforcing our mission to deliver impactful healthcare solutions.”

“This collaboration is not just about expanding our portfolio; it’s about making a real difference in the fight against opioid addiction,” added Shankar Hariharan, Ph.D., CEO of Scienture, LLC. “By working alongside public health agencies and community organizations, we will drive meaningful change and save lives.”

“As part of our commitment to fast-tracking healthier tomorrows, we are thrilled to be joining forces with Scienture to bring this life-saving device to market,” remarked Milton Boyer, CEO of Kindeva. “Our nasal drug delivery team has created a nasal spray that is quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States. We are dedicated to ensuring this device reaches the people that need it most as quickly as possible and prevent more opioid related fatalities.”

About REZENOPY®

REZENOPY® (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.

REZENOPY® nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT SAFETY INFORMATION

Administration: REZENOPY® nasal spray is for intranasal use only. Seek emergency medical care immediately after use. Administer a single spray into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Do not administer more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
Contraindications: REZENOPY® nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
Warnings and Precautions:
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
Adverse Reactions: The following adverse reactions were observed in a REZENOPY® nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
Storage and Handling: Store REZENOPY® nasal spray in the blister and cartons provided. Store between 2°C to 25°C (36°F to 77°F). Excursions permitted up to 40°C (104°F). Do not freeze or expose to excessive heat above 40°C (104°F). Protect from light. REZENOPY® nasal spray may freeze at cold temperatures. If this happens, the device will not spray. If REZENOPY® nasal spray is frozen and is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.
For more detailed information, please refer to the full prescribing information provided by the FDA.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit www.scienture.com.

About Kindeva Drug Delivery L.P.

Kindeva Drug Delivery is a leading global powerhouse CDMO for sterile injectable, pulmonary, nasal, transdermal, and intradermal finished dose. We are committed to manufacturing more tomorrows for our customers, colleagues, and patients around the world. We deliver unrivaled expertise across development, manufacturing, and comprehensive analytical services for a broad range of drug-delivery formats. Through strategic investments in cutting-edge technology, we proactively tackle critical industry challenges, including expanding aseptic injectable fill-finish capabilities and leading the way in green propellant initiatives. Combining forces with a diverse global client base, Kindeva operates state-of-the-art manufacturing, research, and development facilities across the U.S. and U.K. For more information please visit www.kindevadd.com

1st ever,nasal narcan,big$(whole mkt is theirs!)astronomical greed potential makes tickers run
It’s about to be launched,already fda approved,waiting for another FDA today,omg